Get Premium to unlock powerful stock data

Top 5 1st Quarter Trades of ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

Author's Avatar
insider
May 16, 2022
Article's Main Image

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP recently filed their 13F report for the first quarter of 2022, which ended on 2022-03-31.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

200 CLARENDON STREET, 30TH FLOOR BOSTON, MA 02116

As of the latest 13F report, the guru’s equity portfolio contained 1151 stocks valued at a total of $80,049,000,000. The top holdings were MSFT(6.67%), GOOG(2.48%), and AAPL(1.91%).

According to GuruFocus data, these were ARROWSTREET CAPITAL, LIMITED PARTNERSHIP’s top five trades of the quarter.

UnitedHealth Group Inc


During the quarter, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP bought 2,540,538 shares of NYSE:UNH for a total holding of 2,691,542. The trade had a 1.61% impact on the equity portfolio. During the quarter, the stock traded for an average price of $481.86.

On 05/16/2022, UnitedHealth Group Inc traded for a price of $485.4 per share and a market cap of $455,388,496,000. The stock has returned 20.23% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 9 out of 10.

In terms of valuation, UnitedHealth Group Inc has a price-earnings ratio of 26.57, a price-book ratio of 6.26, a price-earnings-to-growth (PEG) ratio of 2.01, a EV-to-Ebitda ratio of 17.37 and a price-sales ratio of 1.57.

The price-to-GF Value ratio is 1.21, earning the stock a GF Value rank of 3.

Canadian Natural Resources Ltd


The guru established a new position worth 15,512,492 shares in NYSE:CNQ, giving the stock a 1.2% weight in the equity portfolio. Shares traded for an average price of $54.35 during the quarter.

On 05/16/2022, Canadian Natural Resources Ltd traded for a price of $60.83 per share and a market cap of $69,676,442,000. The stock has returned 89.65% over the past year.

GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 7 out of 10.

In terms of valuation, Canadian Natural Resources Ltd has a price-earnings ratio of 9.91, a price-book ratio of 2.37, a price-earnings-to-growth (PEG) ratio of 0.59, a EV-to-Ebitda ratio of 5.56 and a price-sales ratio of 2.45.

The price-to-GF Value ratio is 1.18, earning the stock a GF Value rank of 3.

NVIDIA Corp


ARROWSTREET CAPITAL, LIMITED PARTNERSHIP reduced their investment in NAS:NVDA by 3,039,650 shares. The trade had a 1.09% impact on the equity portfolio. During the quarter, the stock traded for an average price of $251.13.

On 05/16/2022, NVIDIA Corp traded for a price of $177.06 per share and a market cap of $515,732,492,000. The stock has returned 29.69% over the past year.

GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 10 out of 10.

In terms of valuation, NVIDIA Corp has a price-earnings ratio of 46.01, a price-book ratio of 16.67, a price-earnings-to-growth (PEG) ratio of 1.43, a EV-to-Ebitda ratio of 44.60 and a price-sales ratio of 16.68.

The price-to-GF Value ratio is 0.71, earning the stock a GF Value rank of 10.

Gilead Sciences Inc


During the quarter, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP bought 13,764,169 shares of NAS:GILD for a total holding of 18,002,214. The trade had a 1.02% impact on the equity portfolio. During the quarter, the stock traded for an average price of $64.

On 05/16/2022, Gilead Sciences Inc traded for a price of $62.37 per share and a market cap of $78,231,530,000. The stock has returned -5.34% over the past year.

GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.

In terms of valuation, Gilead Sciences Inc has a price-earnings ratio of 17.42, a price-book ratio of 3.93, a EV-to-Ebitda ratio of 11.08 and a price-sales ratio of 2.86.

The price-to-GF Value ratio is 0.82, earning the stock a GF Value rank of 10.

AbbVie Inc


During the quarter, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP bought 3,768,579 shares of NYSE:ABBV for a total holding of 4,652,122. The trade had a 0.76% impact on the equity portfolio. During the quarter, the stock traded for an average price of $145.09.

On 05/16/2022, AbbVie Inc traded for a price of $153.5 per share and a market cap of $271,251,398,000. The stock has returned 36.30% over the past year.

GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 10 out of 10.

In terms of valuation, AbbVie Inc has a price-earnings ratio of 22.02, a price-book ratio of 16.66, a price-earnings-to-growth (PEG) ratio of 1.54, a EV-to-Ebitda ratio of 13.62 and a price-sales ratio of 4.81.

The price-to-GF Value ratio is 1.20, earning the stock a GF Value rank of 3.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.

Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles